Welcome to the Starpharma Investor Centre

Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform.

asx.jpg

View All
ASX Announcements

 

Update your
shareholder details

 

Download 
Annual Report

View 
Analyst coverage

 

Submit an Investor query

 

Register for email updates

Watch Starpharma's 2022 Annual General Meeting

  
   

Latest News & Announcements

Click here for news archive

Starpharma presents additional clinical data for DEP® cabazitaxel in prostate cancer (ASX Announcement)

Sep 12th, 2022

Starpharma announces additional results from the mCRPC cohort of its Phase 2 DEP® cabazitaxel trial, following completion of dosing in this cohort. Treatment with DEP® cabazitaxel showed a number of key advantages compared to published data for conventional cabazitaxel, including superior efficacy, as measured by longer PFS, and a lower incidence of key side effects, despite this patient cohort being relatively more heavily pre-treated.

Read More

Starpharma signs new DEP® agreement with MSD (ASX Announcement)

Aug 10th, 2022

Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021. Under the new agreement, Starpharma will design and synthesize a number of DEP® dendrimer conjugates and will provide them to MSD for testing and characterisation.

Read More

 

Reports & Presentations

Click here for financial reports archive

2022 Annual General Meeting - CEO's presentation

Dec 2nd, 2022

View/Download a copy of the CEO's presentation to shareholders at the 2022 Annual General Meeting, held on 29 November 2022.

Read More

Starpharma presents additional clinical data for DEP® cabazitaxel in prostate cancer (ASX Announcement)

Sep 12th, 2022

Starpharma announces additional results from the mCRPC cohort of its Phase 2 DEP® cabazitaxel trial, following completion of dosing in this cohort. Treatment with DEP® cabazitaxel showed a number of key advantages compared to published data for conventional cabazitaxel, including superior efficacy, as measured by longer PFS, and a lower incidence of key side effects, despite this patient cohort being relatively more heavily pre-treated.

Read More